Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
PaperCitations, authors & open-access status
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 282 citations, 2022 year and hybrid oa status.
282
Citations
2022
Year
hybrid
OA Status